文献速递头颈与中枢神经肿瘤

新诊断胶质母细胞瘤放疗前肿瘤负荷与总生存期的关联:按MGMT启动子甲基化状态校正

Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.
PubMed 文献 · Eur J Cancer · 2023-04-28

该回顾性分析纳入CENTRIC与CORE试验中408例新诊断胶质母细胞瘤患者,利用三维分割获取放疗前残余对比增强肿瘤体积与非增强T2w异常组织体积,按MGMT状态校正后评估其与总生存期的关联。结果显示MGMT甲基化者中位OS为117周,非甲基化者为61周;分层后较高CET体积(HR 1.020)与年龄较大(HR 1.664)与更短OS显著相关,而NT2A体积与体能状态无显著关联。

要点

  • MGMT甲基化患者中位OS 117周,非甲基化者61周(p < 0.001)。
  • 校正MGMT状态后,较高放疗前CET体积与更短OS显著相关(HR 1.020)。
  • NT2A体积与体能状态在分层分析中与OS无显著关联。

核心结论

  • 在新诊断胶质母细胞瘤接受替莫唑胺放化疗的患者中,按MGMT启动子甲基化状态分层后,放疗前对比增强肿瘤体积与总生存期强相关。

研究设计与样本

  • 回顾性评估CENTRIC(EORTC 26071-22072)与CORE试验中术后放疗前磁共振成像可用的新诊断胶质母细胞瘤患者。
  • 纳入标准为放疗前4周内完成术后MRI,包含增强前后T1w图像及至少一个T2w序列(T2w或T2w-FLAIR)。
  • 通过三维分割获取放疗前残余对比增强肿瘤体积与非增强T2w异常组织体积,共纳入408例肿瘤分割(其中270例MGMT甲基化)。
  • 采用Cox比例风险模型与Kaplan-Meier估计评估放疗前CET/NT2A体积与OS的关联,并校正年龄、体能状态、MGMT状态等已知预后因素。

主要发现

  • MGMT甲基化肿瘤患者中位OS为117周,MGMT非甲基化肿瘤患者为61周(p < 0.001)。
  • 按MGMT甲基化状态分层后,较高CET体积与更短OS显著相关(HR 1.020;95% CI [1.013-1.027];p < 0.001)。
  • 年龄较大与更短OS显著相关(HR 1.664;95% CI [1.214-2.281];p = 0.002)。
  • NT2A体积与体能状态在分层分析中与OS无显著关联。

关键数值与推荐

  • MGMT甲基化患者中位OS 117周 vs MGMT非甲基化患者61周(p < 0.001)。
  • CET体积每增加一个单位,OS缩短风险HR 1.020(95% CI [1.013-1.027];p < 0.001)。
  • 年龄每增加一个单位,OS缩短风险HR 1.664(95% CI [1.214-2.281];p = 0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We retrospectively evaluated the association between postoperative pre-radiotherapy tumour burden and overall survival (OS) adjusted for the prognostic value of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with newly diagnosed glioblastoma treated with radio-/chemotherapy with temozolomide. MATERIALS AND METHODS: Patients were included from the CENTRIC (EORTC 26071-22072) and CORE trials if postoperative magnetic resonance imaging scans were available within a timeframe of up to 4weeks before radiotherapy, including both pre- and post-contrast T1w images and at least one T2w sequence (T2w or T2w-FLAIR). Postoperative (residual) pre-radiotherapy contrast-enhanced tumour (CET) volumes and non-enhanced T2w abnormalities (NT2A) tissue volumes were obtained by three-dimensional segmentation. Cox proportional hazard models and Kaplan Meier estimates were used to assess the association of pre-radiotherapy CET/NT2A volume with OS adjusted for known prognostic factors (age, performance status, MGMT status). RESULTS: 408 tumour (of which 270 MGMT methylated) segmentations were included. Median OS in patients with MGMT methylated tumours was 117 weeks versus 61weeks in MGMT unmethylated tumours (p < 0.001). When stratified for MGMT methylation status, higher CET volume (HR 1.020; 95% confidence interval CI [1.013-1.027]; p < 0.001) and older age (HR 1.664; 95% CI [1.214-2.281]; p = 0.002) were significantly associated with shorter OS while NT2A volume and performance status were not. CONCLUSION: Pre-radiotherapy CET volume was strongly associated with OS in patients receiving radio-/chemotherapy for newly diagnosed glioblastoma stratified by MGMT promoter methylation status.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Alafandi A, van Garderen KA, Klein S, et al. Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status. Eur J Cancer. 2023. PMID: 37235895. doi:10.1016/j.ejca.2023.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。